Netflix to Acquire Warner Bros. Following the Separation of Discovery Global for $72.0 Billion

Staff Writer

-

December 5, 2025

Netflix to Acquire Warner Bros. Following the Separation of Discovery Global for $72.0 Billion

Today, Netflix, Inc. (the Company) and Warner Bros. Discovery, Inc. (WBD) announced they have entered into a definitive agreement under which Netflix will acquire Warner Bros., including its film and television studios, HBO Max and HBO.

The cash and stock transaction is valued at $27.75 per WBD share (subject to a collar as detailed below), with a total enterprise value of approximately $82.7 billion (equity value of $72.0 billion). The transaction is expected to close after the previously announced separation of WBD’s Global Networks division, Discovery Global, into a new publicly-traded company, which is now expected to be completed in Q3 2026.

This acquisition brings together two pioneering entertainment businesses, combining Netflix’s innovation, global reach and best-in-class streaming service with Warner Bros.’ century-long legacy of world-class storytelling. Beloved franchises, shows and movies such as The Big Bang Theory, The Sopranos, Game of Thrones, The Wizard of Oz and the DC Universe will join Netflix’s extensive portfolio including Wednesday, Money Heist, Bridgerton, Adolescence and Extraction, creating an extraordinary entertainment offering for audiences worldwide.

“Our mission has always been to entertain the world,” said Ted Sarandos, co-CEO of Netflix. “By combining Warner Bros.’ incredible library of shows and movies—from timeless classics like Casablanca and Citizen Kane to modern favorites like Harry Potter and Friends—with our culture-defining titles like Stranger Things, KPop Demon Hunters and Squid Game, we’ll be able to do that even better. Together, we can give audiences more of what they love and help define the next century of storytelling.”

“This acquisition will improve our offering and accelerate our business for decades to come,” continued Greg Peters, co-CEO of Netflix. “Warner Bros. has helped define entertainment for more than a century and continues to do so with phenomenal creative executives and production capabilities. With our global reach and proven business model, we can introduce a broader audience to the worlds they create—giving our members more options, attracting more fans to our best-in-class streaming service, strengthening the entire entertainment industry and creating more value for shareholders.”

“Today’s announcement combines two of the greatest storytelling companies in the world to bring to even more people the entertainment they love to watch the most,” said David Zaslav, President and CEO of Warner Bros. Discovery. “For more than a century, Warner Bros. has thrilled audiences, captured the world’s attention, and shaped our culture. By coming together with Netflix, we will ensure people everywhere will continue to enjoy the world’s most resonant stories for generations to come.”

Combination Will Offer More Choice, More Opportunities, More Value

Complementary strengths and assets: Warner Bros.’ studios are world-class, with Warner Bros. recognized as a leading supplier of television titles and filmed entertainment. HBO and HBO Max also provide a compelling, complementary offering for consumers. Netflix expects to maintain Warner Bros.’ current operations and build on its strengths, including theatrical releases for films.
More choice and greater value for consumers: By adding the deep film and TV libraries and HBO and HBO Max programming, Netflix members will have even more high-quality titles from which to choose. This also allows Netflix to optimize its plans for consumers, enhancing viewing options and expanding access to content.
A stronger entertainment industry: This acquisition will enhance Netflix’s studio capabilities, allowing the Company to significantly expand U.S. production capacity and continue to grow investment in original content over the long term which will create jobs and strengthen the entertainment industry.
More opportunities for the creative community: By uniting Netflix’s member experience and global reach with Warner Bros.’ renowned franchises and extensive library, the Company will create greater value for talent—offering more opportunities to work with beloved intellectual property, tell new stories and connect with a wider audience than ever before.
More value for shareholders: By offering members a wider selection of quality series and films, Netflix expects to attract and retain more members, drive more engagement and generate incremental revenue and operating income. The Company also expects to realize at least $2-3 billion of cost savings per year by the third year and expects the transaction to be accretive to GAAP earnings per share by year two.

Transaction Details and Timing

Under the terms of the agreement, each WBD shareholder will receive $23.25 in cash and $4.50¹ in shares of Netflix common stock for each share of WBD common stock outstanding at the closing of the transaction. The transaction values Warner Bros. Discovery at $27.75 per share, implying a total equity value of approximately $72.0 billion and an enterprise value of approximately $82.7 billion

In June 2025, WBD announced plans to separate its Streaming & Studios and Global Networks divisions into two separate publicly traded companies. This separation is now expected to be completed in Q3 2026, prior to the closing of this transaction. The newly separated publicly traded company holding the Global Networks division, Discovery Global, will include premier entertainment, sports and news television brands around the world including CNN, TNT Sports in the U.S., and Discovery, free-to-air channels across Europe, and digital products such as Discovery+ and Bleacher Report.

The stock component is subject to a collar under which WBD shareholders will receive Netflix stock valued at $4.50 per share, provided the 15-day volume weighted average price (“VWAP”) of Netflix stock price (measured three trading days prior to closing) falls between $97.91 and $119.67. If the VWAP is below $97.91, WBD shareholders will receive 0.0460 Netflix shares for each WBD share. If the VWAP is above $119.67, WBD shareholders will receive 0.0376 Netflix shares for each WBD share.

The transaction was unanimously approved by the Boards of Directors of both Netflix and WBD. In addition to the completion of the separation of Discovery Global (WBD’s Global Networks business), completion of the transaction is subject to required regulatory approvals, approval of WBD shareholders and other customary closing conditions. The transaction is expected to close in 12-18 months.

Moelis & Company LLC is acting as Netflix’s financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal counsel. Wells Fargo is acting as an additional financial advisor and, along with BNP and HSBC, is providing committed debt financing related to the transaction.

Allen & Company, J.P. Morgan and Evercore are serving as financial advisors to Warner Bros. Discovery and Wachtell Lipton, Rosen & Katz and Debevoise & Plimpton LLP are serving as legal counsel.

More here: https://about.netflix.com/en/news/netflix-to-acquire-warner-bros

Former FDA, CRO, and Industry Leader Dr. Stephine Keeton Joins MMS as Senior Director of Biometrics

Staff Writer

-

December 4, 2025

0

Former FDA, CRO, and Industry Leader Dr. Stephine Keeton Joins MMS as Senior Director of Biometrics

MMS, a global, data-focused clinical research organization (CRO), announced today that Stephine Keeton, PhD, has joined the company as Senior Director of Biometrics. Her appointment comes against an industry backdrop of rising trial and data complexity, alongside intensifying pressure on sponsors to accelerate cycle times and enhance productivity. With experience spanning regulatory, biopharma, and CRO environments, Dr. Keeton is uniquely positioned to strengthen MMS’ specialist biometrics capabilities and support sponsors in addressing today’s expanding clinical data challenges. Immediately prior to joining MMS, she led biostatistics at Altimmune, a clinical-stage biopharmaceutical company, and has previously served within the FDA in statistical roles for more than seven years.

“Stephine’s expansive experience across diverse settings will add significant value to our biometrics leadership team, in turn delivering value to our global biopharmaceutical clients,” said Chris Schoonmaker, Chief Operating Officer at MMS. “Her appointment comes at an inflection point for our industry, as sponsors increasingly look for specialized partners who can guide them through complex data challenges and deliver high-quality, submission-ready results.”

Michelle Gayari, Executive Vice President of Global Operational Excellence and Innovation added, “Stephine’s leadership will help us continue to advance our approach to biometrics, including integration of AI and automation across the data lifecycle, and partner with our clients to achieve their development goals.”

MMS delivers end-to-end biometrics solutions, integrating biostatistics, statistical programming, data management, data science, medical writing, and pharmacovigilance to support sponsors from trial design through regulatory submission.

Dr. Keeton said, “I am excited to join MMS at a time when the role of biometrics in clinical development is more critical than ever, and the opportunities to innovate are vast. Throughout my career, I’ve seen firsthand how the combination of thoughtful statistical planning, robust data strategy, and regulatory foresight shapes the success of clinical trials. I’m looking forward to working with a team that is so deeply committed to scientific excellence and operational innovation, and to helping our clients reduce their risk while accelerating the development of new therapies.”

With a global footprint across four continents, MMS anchors its biometrics solutions in quality-by-design and proactive data risk management, complemented by deep capabilities in trial design and regulatory strategy. Leveraging advanced technologies, including Datacise ® for real-time data visualization and analytics, and KerusCloud ® for clinical trial simulation and design optimization, MMS equips sponsors with the insights needed to maintain data integrity, anticipate risk, and ensure regulatory readiness at every stage. This holistic approach brings deep expertise, optimized processes, and advanced technologies to deliver the flexibility and strategic support sponsors need to thrive in an increasingly demanding data and regulatory environment.

Dr. Keeton’s appointment further strengthens MMS’ leadership as a data-focused CRO, and reinforces the company’s mission to support the development of therapies that make a meaningful difference for patients.

To learn more about biometrics solutions at MMS, visit https://mmsholdings.com/solutions/full-service-biometrics/.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, a 19-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across five continents, MMS maintains an industry-leading customer satisfaction rating. For more information, visit www.mmsholdings.com.

PumasAI’s AskPumas Surpasses 15,000 Questions Answered as Global Use of AI Tools in Drug Development Accelerates

Staff Writer

-

December 2, 2025

0

PumasAI’s AskPumas Surpasses 15,000 Questions Answered as Global Use of AI Tools in Drug Development Accelerates

PumasAI, a science-first organization that turns data into life-saving decisions faster, announced today that AskPumas, its secure Retrieval Augmented Generation (RAG) tool built for clinical pharmacologists and pharmacometricians, has just surpassed 15,000 questions answered.

AskPumas is an AI assistant that delivers trusted, on-demand access to field-specific knowledge by integrating a curated list of sources, giving pharmacometricians and clinical pharmacologists accurate, source-backed answers grounded in validated content.

“AskPumas was built for scientists who need answers they can stand behind, and this milestone signals the growing confidence of scientists in using artificial intelligence in drug development,” said Dr. Vijay Ivaturi, Co-Founder and CEO of PumasAI. “We focused on real scientific workflows and created something dependable that our friends and colleagues would actually use. That is why we are seeing adoption grow rapidly.”

The AI needed in pharma and biotech

AskPumas is part of a broader AI strategy at PumasAI to help teams access insights quicker in a safe and repeatable way. Upcoming workflow automation features will continue to extend its value across model-informed drug development teams.

Key features of AskPumas include the following:

Curated Knowledge Resources: Through its constantly updated, focused resource base, the tool provides more relevant answers than generic large language models (LLMs).
Improved Accuracy: By focusing on reducing hallucinations and ensuring human verification of AI responses, AskPumas provides reliable, source-backed information.
Language Flexibility: Users can gain responses in multiple languages, and the system translates all PumasAI tutorials and documentation with ease.

“AskPumas is doing what pharmacometricians have always needed, supporting their work with fast and accurate access to curated knowledge relevant to the pharmacometrician,” said Dr. Andreas Noack, VP of Product Development at PumasAI.

More than 1,400 scientists across 260 institutions are now using PumasAI tools. The company continues to support innovation in academia by offering its solutions at no cost to academic institutions worldwide. Universities and academic researchers can gain free access to PumasAI tools by following the instructions at https://pumas.ai/our-products/pumas-for-academia.

To learn more or request a demo of AskPumas, visit https://pumas.ai/ or watch the video at https://youtu.be/LxY2ofCVX8E?si=dcS7HIgv5YaelmgE&t=232.

About PumasAI

PumasAI is an award-winning global healthcare intelligence company with a vision to accelerate precision healthcare to patients. Proprietary software and AI tools developed by the company include an integrated modeling and simulation platform designed to multiply productivity across the drug development lifecycle as well as a range of specialized solutions for data analytics, machine learning, clinical trial optimization, and regulatory compliance. Scientists at PumasAI partner with leading pharmaceutical innovators, providing expert consulting in clinical pharmacology, model-informed drug development (MIDD), pharmacometrics, front-end applications, and more. By streamlining modeling, simulation, and data analytics, their solutions empower scientists and pharmaceutical partners to accelerate breakthroughs and deliver transformative healthcare. For additional information, visit www.pumas.ai.

Respected Data Science Industry Leader Chris Hurley Joins TrialAssure Advisory Leadership Team to Strengthen Data Strategy and Innovation

-

December 2, 2025

0

CANTON, Mich. (December 2, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced today that Chris Hurley, MBA, Americas Director for PHUSE and former Director of Data Science at MMS, has joined TrialAssure’s Advisory Leadership Team. In this role, Hurley will provide strategic guidance on the company’s data strategy and help shape the future of TrialAssure’s technology platforms and analytics capabilities.

Hurley brings more than 35 years of experience across clinical data workflows, SAS programming, and regulatory submission support. As Director of Data Science at MMS, he led cross-functional initiatives that bridge programming, statistics, and automation. His ability to translate technical processes into scalable, business-ready solutions makes him a strong addition to TrialAssure’s advisory group as the company continues to expand its footprint in AI-powered pharma and biotech industry tools.

“Chris has a unique combination of deep technical experience and an intuitive understanding of how data can accelerate smarter, faster decision-making across the drug development lifecycle,” said Prasad M. Koppolu, Chief Operating Officer (COO) at TrialAssure. “His contributions will help us evolve our platform strategy to meet the needs of global sponsors, regulators, and patients.”

Hurley entered the pharmaceutical industry in 1990 at Warner-Lambert/Parke-Davis, which later became part of Pfizer, and has held leadership roles across both Sponsor and CRO settings. Recognized throughout the industry for his technical leadership and collaborative approach, Hurley is known for his mentorship, process development, and active engagement in global forums.

“I’m excited to join TrialAssure’s Advisory Leadership Team and contribute to its mission of building smarter tools for the life sciences industry,” said Hurley. “Data strategy is critical to innovation in clinical research, and TrialAssure is leading the charge with anonymization and generative AI technology that makes a measurable impact.”

TrialAssure continues to expand its advisory network with respected leaders across regulatory science, medical writing, AI, and clinical operations. Hurley’s appointment reflects the company’s ongoing investment in expert-driven growth and innovation.

To learn more about TrialAssure solutions, visit https://www.trialassure.com/software/.

ABOUT TRIALASSURE

TrialAssure® is an award-winning global data transparency company providing fast, intelligent, and cost-effective software and services for the pharmaceutical industry and related sectors. A recognized leader in artificial intelligence (AI) and machine learning (ML), TrialAssure offers AI Enabled, Human Driven™ solutions that support compliance through document and data anonymization, AI-assisted content development, compliance tracking, and clinical trial disclosure. Founded in 2009, TrialAssure’s global team builds proven technology platforms that help Sponsors and research organizations stay aligned with transparency regulations worldwide. TrialAssure was named Data Solution of the Year by the Data Breakthrough Awards.

For more information, visit www.trialassure.com.

Hemmings Announces 40 Percent Reduced Buyer’s Fees on Select Auctions for Cyber Monday

Staff Writer

-

November 25, 2025

0

Hemmings Announces 40 Percent Reduced Buyer’s Fees on Select Auctions for Cyber Monday

A curated lineup of auctions goes live Nov. 24 and ends Dec. 1

CHARLOTTE, NC/BENNINGTON, VT (November 20, 2025) — Hemmings, the world’s largest online, collector car marketplace, today announced its Cyber Monday collector car deal of the year, offering a 40 percent discount on buyer’s fees for select Hemmings Auctions. Eligible auctions launch on Monday, November 24 and close on Monday, December 1, 2025.

Just in time for the holiday season, this special offer gives automotive enthusiasts the chance to bid on a curated lineup of standout collector vehicles, ranging from early hot rods and American muscle to rare European classics and offroad icons.

“Cyber Monday gives us a chance to welcome new buyers into the Hemmings experience,” said Jonathan Shaw, President of Hemmings. “The reduced buyer’s fee opens the door to discover exceptional vehicles and enjoy our marketplace at its best.”

Hemmings Cyber Monday Offer Details

The Offer: 40 percent off the standard buyer’s fee (5%) for select Hemmings Auctions, reducing the buyer’s fee to 3% for one day only.
The Auctions: Eligible auctions launch on Monday, November 24, 2025 and close on December 1, 2025, highlighted at https://www.hemmings.com/ by special badging on the auction’s lead image.
How to Participate: Buyers must register to bid by creating a FREE Hemmings account at hmn.com/cybermonday

About Hemmings

Founded in 1954, Hemmings is the world’s largest online collector car marketplace. For more than 70 years, we have grown and uplifted the collector car community because we’ve been part of it since the start. Through our frictionless marketplace, quality entertainment, and professional service, we help all willing drivers buy, sell, and live the collector car lifestyle. Hemmings Motor Club extends this mission by bringing enthusiasts together through exclusive benefits, curated driving experiences, and deeper community connections for those who live to drive. More information, services, and content are available at https://www.hemmings.com/. Stay connected with Hemmings on Facebook, Instagram, and YouTube, and search tens of thousands of vehicle listings from the palm of your hand with the Hemmings App.

MMS Brings Biometrics and AI Leadership to PHUSE EU Connect 2025 and Previews Accepted Presentations for US Connect 2026

Life Sciences

Staff Writer

-

November 14, 2025

0

MMS Brings Biometrics and AI Leadership to PHUSE EU Connect 2025 and Previews Accepted Presentations for US Connect 2026

MMS, a global, data-focused clinical research organization (CRO), is set to bring fresh insights and hands-on engagement to PHUSE EU Connect 2025, taking place in Hamburg, Germany, from November 16-19, 2025, at CCH – Congress Center Hamburg.

James Zee, Director of Statistical Programming at MMS, will deliver the presentation “Rethinking Automation in the AI Era” on Wednesday, November 19 at 12:00 PM, as part of the Machine Learning, AI, and LLM stream (Paper ML13). The session will explore through specific use cases how intelligent automation and artificial intelligence alongside human expertise are already accelerating drug development and improving quality. Zee will draw on his experience working directly with advanced technologies such as Datacise ®, an innovative, cloud-based technology platform from MMS that enables biotechnology and pharmaceutical companies to more efficiently curate, analyze, and visualize clinical and real-world data to accelerate decision-making.

Additionally, MMS will host a new interactive game, Rooftop Runner – Conquer Your Clinical Challenges!, at exhibit booth 22. Attendees are invited to test their data instincts, compete for a high score, and enter to win Amazon vouchers, all while learning how MMS simplifies complexity through intuitive visualizations and data-first technology.

Looking Ahead to PHUSE US Connect 2026

MMS is also excited to announce that three abstracts have been accepted for the upcoming PHUSE US Connect 2026, taking place March 22–26, 2026 in Austin, Texas. Topics will explore the evolving role of AI in biometrics, and the importance of cross-functional collaboration to drive better outcomes.

MMS’ presentations include the following:

Building Cross-Functional Regulatory and Programming Alignment for Successful Submissions – Ben Kaspar, VP of Regulatory Strategy, and James Zee, Director of Statistical Programming, MMS
What Pharma Can Learn from Data Science Outside the Industry – Kris Wenzel, Sr. Manager of Data Science, MMS
Estimand-Aligned Multiple Imputation Strategies in CNS Trials with Complex Intercurrent Events – Veera Thota, Manager, Statistical Programming, MMS

Meet the MMS Team in Hamburg

Attendees at this year’s PHUSE EU Connect 2025 are encouraged to attend James Zee’s talk, stop by the MMS booth to experience Rooftop Runner, and connect with our biometrics leaders who are shaping the future of efficient, compliant, and data-driven clinical research.

To connect with any of the presenters or to schedule a meeting, visit https://mmsholdings.com/contact/.

About MMS

MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, a 19-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across five continents, MMS maintains an industry-leading customer satisfaction rating.

For more information, visit www.mmsholdings.com.

Cliniphai and Nested Knowledge Announce Partnership at ISPOR Europe 2025 to Accelerate Global Health Technology Assessment (HTA) Dossier Localization with AI

Staff Writer

-

November 13, 2025

0

Cliniphai and Nested Knowledge Announce Partnership at ISPOR Europe 2025 to Accelerate Global Health Technology Assessment (HTA) Dossier Localization with AI

Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, announced a strategic partnership with Nested Knowledge, a leader in evidence review technology, today to streamline and accelerate the preparation and submission of localized Health Technology Assessment (HTA) dossiers globally. The partnership was formalized during the ISPOR Europe 2025 conference at the Scottish Event Campus in Glasgow this week.

This collaboration will combine Cliniphai’s localization platform, Athena, and its strategic partner Gibson Research Consultancy (GRC), a global leader in linguistic validation and user-centered research, to deliver AI-enabled human-in-the-loop (HITL) translations for dossier components from Nested Knowledge’s powerful systematic evidence synthesis platform.

Together, the companies are solving a critical bottleneck in HTA dossier localization by delivering the following:

AI-powered evidence synthesis through Nested Knowledge’s systematic literature review and indirect treatment comparison tools.
Expert-led, HITL translations via Cliniphai’s Athena platform and GRC-vetted linguists.
Rapid adaptation of HTA dossiers to meet the needs of global health authorities.
Improved accuracy and compliance through built-in regulatory alignment and operational transparency.

“Our goal is to help our clients accelerate study startup activities, and deliver needed therapies to patients worldwide,” said Jason Martin, MS, co-founder and Chairman at Cliniphai. “Partnering with Nested Knowledge allows us to dramatically reduce the time required to translate clinical evidence into HTA submissions and adapt them for various global requirements, utilizing our compliant GRC-based talent model. This efficiency is crucial for navigating complex regulatory landscapes.”

The partnership addresses the complexity and time burden of adapting comprehensive HTA dossiers for different regulatory bodies and local languages worldwide. By leveraging the AI and machine-learning capabilities of the Nested Knowledge platform, the companies will rapidly enhance the core evidence synthesis (SLRs and ITCs). Crucially, Cliniphai then utilizes its platform to engage a network of GRC-vetted local regulatory and specialized linguists to ensure rapid, accurate, and compliant localization of these complex documents.

Keith Kallmes, co-founder and President of Nested Knowledge, added “Cliniphai has built an exciting modern platform to expand the capabilities that Nested Knowledge is providing its customers. By integrating Cliniphai’s AI-accelerated localization platform and language expertise from GRC with our data synthesis tools, we are jointly empowering life science companies to create high-quality HTA dossiers with unprecedented speed. This partnership is a force multiplier for helping companies looking to accelerate the translations and preparations of their HTAs to support market access.” To schedule a call to learn more, visit: https://cliniphai.com/contact-us/.

EyeCheq and CoPeace Health Launch Alliance to Deploy AI-Powered Vision Screening in America’s “Eye-Care Deserts”

Staff Writer

-

November 10, 2025

0

EyeCheq and CoPeace Health Launch Alliance to Deploy AI-Powered Vision Screening in America’s “Eye-Care Deserts”

In a landmark move to advance health equity, EyeCheq, a pioneer in AI-powered eye health technology, today announced a strategic partnership with CoPeace Health PBC, the impact-driven health subsidiary of CoPeace PBC. The alliance is set to deploy revolutionary vision and diabetic retinopathy screenings across rural and Native American communities, tackling the long-standing crisis of “eye-care deserts” with accessible, on-site technology.

This partnership directly addresses a critical healthcare failure: millions of Americans in remote areas lack access to basic eye care, placing them at high risk for preventable blindness, especially from diabetes. By placing EyeCheq’s self-guided kiosks in community health centers, tribal health systems, and rural clinics, CoPeace Health will bridge this gap, bringing sight-saving diagnostics directly to the people who need them most.

Why This Changes Everything

Immediate, Local Screening: The EyeCheq kiosk delivers a comprehensive, 5-minute screening—including a vision assessment and retinal imaging for diabetic retinopathy—slashing wait times from months to minutes and enabling immediate intervention.
Seamless Clinical Integration: Exams are interpreted remotely by licensed, in-state eye care specialists. Preliminary results are displayed instantly at the kiosk, while detailed reports are sent to the EyeCheq patient portal, empowering both patients and their care teams.
Driving Health Equity & Efficiency: This model helps clinics meet critical HEDIS/Stars quality measures for diabetic eye exams, dramatically reduce rates of avoidable blindness, and illuminate care deserts—all with a minimal burden on existing staff.
Designed for Rapid, Scalable Deployment: With a compact footprint and plug-and-play setup, the kiosks are ideal for Federally Qualified Health Centers (FQHCs), Indian Health Service (IHS) sites, pharmacies, and employer clinics.

“This is about more than technology; it’s about restoring dignity and preventing irreversible vision loss,” said Dr. Rashid Taher, CEO of EyeCheq. “For too long, your zip code has determined your access to sight-saving care. Partnering with CoPeace Health gives us the reach to change that. We are delivering a solution that is not only powerful and affordable but designed with cultural respect at its core.”

“EyeCheq has cracked the code on one of the most persistent challenges in preventative medicine: reaching the unreachable,” said Andy Eckert, President of CoPeace Health PBC. “This isn’t just about deploying hardware; it’s about deploying hope. Together, we will deliver thousands of screenings across historically marginalized communities, turning data into life-changing outcomes and proving that impact-focused business can solve our most pressing healthcare challenges.”

The Complete Solution

The EyeCheq Kiosk: A 5-minute, self-guided experience delivering retinal imaging and vision diagnostics.
Expert Remote Interpretation: Secure analysis by licensed, in-state specialists providing clear, actionable guidance.
Actionable, Integrated Reporting: Results are delivered via a patient portal and documented for provider records and quality metric reporting.
Built for the Front Lines: Self-service minimizing staffing requirements, rapid installation, and seamless alignment with payer quality incentives.

The Path to Impact

CoPeace Health will spearhead priority deployments with tribal health authorities and rural health networks, focusing initially on regions with the highest prevalence of diabetes and the most severe shortages of specialists. This phased rollout will be guided by clinical outcomes and community feedback, with a long-term vision of establishing a new national standard for accessible eye care.

About EyeCheq

EyeCheq is revolutionizing preventative health with its intuitive, kiosk-based retinal imaging and AI-assisted screening platform. By enabling the earliest possible detection of vision-threatening diseases like diabetic retinopathy, EyeCheq empowers providers to close care gaps, meet quality measures, and eliminate avoidable blindness. Learn more at https://www.eyecheq.com.

About CoPeace Health PBC

CoPeace Health PBC, a subsidiary of CoPeace PBC, is dedicated to advancing health equity by investing in and partnering with transformative companies. By championing sustainable and scalable solutions, CoPeace Health empowers underserved communities with the tools and access needed to achieve better health outcomes for all. Learn more at https://copeace.com.

Forward-Looking Statements: This release may contain forward-looking statements regarding product capabilities, deployment timelines, and anticipated outcomes. Actual results may differ due to regulatory, operational, or market factors.

TimeShark Announces Integration with OpenTable to Automate Reservations With Voice AI

Staff Writer

-

November 10, 2025

0

TimeShark Announces Integration with OpenTable to Automate Reservations With Voice AI

TimeShark, a leading voice AI platform for hospitality, today announced an integration with OpenTable, a global leader in restaurant tech.. The partnership enables OpenTable customers using TimeShark Voice AI to automate customer calls, enhance efficiency, and handle reservations seamlessly using AI-powered voice technology integrations.

Through the integration, TimeShark connects directly with OpenTable to create, modify, and confirm reservations automatically. Guests calling a restaurant can check availability or make changes instantly through a natural, on-brand voice experience. The integration allows restaurants to manage calls at any hour — reducing missed reservations and freeing staff to focus on in-person hospitality.

Impact & Benefits

TimeShark’s AI has already handled millions of calls for restaurants nationwide, helping operators reduce missed calls by up to 85% and capture 25% more confirmed reservations and private event inquiries through automated booking flows and notifications. The partnership extends those benefits to OpenTable users, offering a seamless way to scale service quality and guest satisfaction while maintaining operational efficiency.

Availability

OpenTable customers can activate the TimeShark integration by contacting TimeShark at opentable@timeshark.ai or via OpenTable’s Integration Marketplace.

About TimeShark

TimeShark is a voice AI platform built for modern hospitality. TimeShark answers calls, automates reservations, and routes event and catering inquiries — reflecting each brand’s unique tone of voice and operating rules, 24/7. Trusted by restaurants across the U.S., TimeShark helps teams save time, reduce missed calls, and deliver consistent guest experiences at scale. Learn more at timeshark.ai.

About OpenTable

OpenTable, a global leader in restaurant tech and part of Booking Holdings, Inc.(NASDAQ:BKNG), helps more than 60,000 restaurants worldwide fill 1.9 billion seats a year. OpenTable’s world-class technology empowers restaurants to focus on what matters most – their team, their guests, and their bottom line – while enabling diners to discover and book the perfect restaurant for every occasion.

James Hardie Crowns Iron Gray as 2026 Color of the Year

Staff Writer

-

November 10, 2025

0

James Hardie Crowns Iron Gray as 2026 Color of the Year

James Hardie Building Products Inc. (James Hardie), the North American leader in fiber cement exterior design solutions, proudly announces its 2026 Color of the Year: Iron Gray. This deep, bold color from the Statement Collection^®product line provides a dramatic yet elegant look for your home exterior.

Iron Gray Hardie® Plank siding with Select Cedarmill® texture

Iron Gray Hardie® Plank siding with Arctic White Hardie® Trim

Hardie^® products in Iron Gray can help homeowners create a house that everyone notices and admires with its rich depth and intensity. Iron Gray commands attention without overwhelming, striking the perfect balance between strength and sophistication. This refined neutral reflects a new era of exterior design, offering subtle drama with timeless appeal. Incredibly versatile, Iron Gray pairs beautifully with crisp accents such as Hardie^®Trim in Arctic White, delivering a clean architectural contrast that elevates a home’s curb appeal. For a more contemporary look, it can also create a powerful, monochromatic statement when paired with matching Iron Gray trim.

“Color has the power to amplify a home’s architectural voice,” said Samara Toole, Chief Marketing Officer of James Hardie. “With Iron Gray, we wanted a color that is expressive yet grounded, one that complements strong lines and invites highlight trims to pop. It’s exactly the kind of color homeowners and professionals are asking for – bold yet timeless.”

Statement Collection^®products, all available with ColorPlus^®Technology finishes, contain up to 19 gorgeous and well-edited colors including Iron Gray. Instead of feeling overwhelmed by choices, you’ll feel empowered by these tried-and-true options curated by James Hardie’s color experts.

ColorPlus^® Technology finishes by James Hardie combine distinct beauty and high performance. It’s the easiest way to choose a gorgeous color for your house and feel confident in its staying power and fade resistance.

James Hardie empowers homeowners and building professionals alike to achieve their dream home with premium, high quality solutions. Using the Hardie™ Designer powered by Hover^®, you can see how different colors, styles, and materials would look on your home with AI-driven visualizations. Visit JamesHardie.com/HardieDesigner to upload a single photo of your home, and in just a few clicks, the Hardie™ Designer can show you how Iron Gray would come to life on your next project.

Hardie^® siding is designed for durability, resisting damage from external fire*, harsh weather, and pests. Hardie^® products with ColorPlus^® Technology finishes resist fading and effects of UV light. James Hardie provides a limited warranty for ColorPlus^® Technology finishes that covers paint and labor and protects against peeling, cracking and chipping for up to 15 years. All Hardie^® fiber cement siding products also come with a 30-year non-prorated limited substrate warranty for added peace of mind. Only Hardie^® siding is Engineered for Climate^® to withstand wet or freezing conditions in the North and hot, humid conditions and blistering sun in the South.

James Hardie brings unmatched credibility and design authority to the siding category, enabling customers to make confident, enduring choices. For more information on James Hardie’s 2026 Color of the Year, Iron Gray, and to explore the full range of Hardie^® products available in this bold color please visit JamesHardie.com. Homeowners and pros alike can also share photos of their Iron Gray exterior siding projects on social media using #JHColorOfTheYear.

About James Hardie Building Products Inc.
James Hardie is the North American leader in fiber cement exterior design solutions. Hardie^® products offer long lasting beauty and endless design possibilities with trusted protection and low maintenance. As the #1 producer of high-performance fiber cement building solutions in the United States, James Hardie offers siding and accessories for every style. Hardie^® products are non-combustible* and stand up to weather and time while empowering homeowners and building professionals to achieve the home of their dreams. James Hardie operates with an inclusive company culture and an unwavering commitment to Zero Harm. The company proudly employs a diverse workforce of over 3,700 employees in North America.

For more information and media resources, visit JamesHardie.com and JamesHardie.com/all-about-james-hardie/media-resources.

For investor information, please visit ir.JamesHardie.com.au.

*Hardie^® fiber cement products are noncombustible and/or have a Class A fire rating when tested in accordance with ASTM E84. Fiber cement fire resistance does not extend to applied paints or coatings, which may be damaged or char when exposed to flames. The use of noncombustible siding, combined with other fire mitigation measures, may help harden a home against external fire.

NewsWeekPRO

Boardroom Buzz

Today, Netflix, Inc. (the Company) and Warner Bros. Discovery, Inc. (WBD) announced they have entered into a definitive agreement under which Netflix will acquire Warner Bros., including its film and television studios, HBO Max and HBO.

Looking Ahead to PHUSE US Connect 2026

Meet the MMS Team in Hamburg

Boardroom Buzz

About us

Company

The latest

Subscribe